Contemporary considerations for neoadjuvant chemotherapy in primary ovarian cancer

Current Oncology Reports

Volumn 11, Issue 6, 2009, Pages 457-465

  Schwartz, Peter E ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; HUMAN; INTERMETHOD COMPARISON; LAPAROSCOPY; MESONEPHROMA; MORBIDITY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL DEFICIENCY; OVARY CANCER; OVERALL SURVIVAL; PARENTERAL NUTRITION; PERITONEUM CANCER; POSTOPERATIVE COMPLICATION; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; REOPERATION; REVIEW; SURGICAL MORTALITY; UTERINE TUBE CARCINOMA;

CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS; OVARIECTOMY; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 70350157197     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-009-0062-y     Document Type: Review

References (50)

1. Schwartz PE: Neoadjuvant chemotherapy for the management of ovarian cancer. Oncol 2008, 22:1118-1125.
2. Chambers JT, Chambers SK, Voynick IM, et al.: Neoadjuvant chemotherapy in stage X ovarian carcinoma. Gynecol Oncol 1990, 37:327-331.
3. Nelson BE, Rosenfield AT, Schwartz PE: Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 1993, 11:166-172.
4. Pecorelli S, Odicino F, Favalli G: Interval debulking surgery in advanced ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2002, 16:573-583.
5. Griffiths CT: Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Mongr 1975, 421:101-104.
6. Griffiths CT, Parker LM, Fuller HFR Jr: Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep 1979, 63:235-240.
7. Hoskins WSJ, Bondy NB, Thigpen JD, et al.: The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 1992, 47:159-166.
8. Crawford SC, Vasey PA, Paul J, et al.: Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from and international comparison within the SCOTROC-1 trial. J Clin Oncol 2005, 23:8802-8811.
9. Crawford SC, Paul J, Kaye SA, et al.: Aggressive surgery and ovarian cancer. J Clin Oncol 2006, 24:2396.
10. Winters WE III, Maxell GL, Tian C, et al.: Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2007, 25:3621-3627.
11. Winters WE III, Maxell GL, Tian C, et al.: Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2008, 26:83-89.
12. DuBois A, Reuss A, Pujade-Lauraine E, et al.: Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. Cancer 2009, 115:1234-1244.
13. McGuire WP, Hoskins WJ, Brady MF, et al.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334:1-6.
14. Jemal A, Siegel R, Ward E, et al.: Cancer statistics 2008. CA Cancer J Clin 2008, 58:71-96.
15. Wils J, Blijham, Naus A, et al.: Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin and cyclophosphamide in stage III-IV epithelial ovarian carcinoma. J Clin Oncol 1986, 4:1068-1073.
16. Neijt JP, ten Bokkel Huinink WW, van der Burg ML, et al.: Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol 1987, 5:1157-1158.
17. Lawton F, Luesley D, Redman C, et al.: Feasibility and outcome of complete secondary tumor resection for patients with advanced ovarian cancer. J Surg Oncol 1990, 45:14-19.
18. van der Burg MEL, van Lent M, Buyse M, et al.: The effect of debulking after induction chemotherapy on the prognosis of advanced epithelial ovarian cancer. N Engl J Med 1995, 332:629-634.
19. Rose PG, Nerenstone S, Brady MF, et al.: Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004, 351:2489-2497.
20. Bristow RE, Chi DS: Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: A meta-analysis. Gynecol Oncol 2006, 103:1070-1076.
21. Bristow RE, Eisenhauer EL, Santillan A, et al.: Delaying the primary surgical effort for advanced ovarian cancer: A systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol 2007, 104:480-490.
22. Hue JY, Kelly MG, Yu H, et al.: Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol Oncol 2007, 105:211-217.
23. Schwartz PE, Chambers JT, Makuch R: Neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol 1994, 53:33-37.
24. Surwit E, Childers J, Atlas I, et al.: Neoadjuvant chemotherapy for advanced ovarian cancer. Int J Gynecol Cancer 1996, 6:356-361.
25. Schwartz PE, Rutherford TJ, Chambers JT, et al.: Neoadjuvant chemotherapy for advanced ovarian cancer: Long-term survival. Gynecol Oncol 1999, 72:93-99.
26. Kang S, Nam BH: Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer?: Meta-analysis of 21 studies. Ann Surg Oncol 2009 (in press).
27. Vergote I, Trope CG, Amant F, et al.: EORTC-GCG/NCIC-CTG randomized trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC-IV ovarian, fallopian tube, and peritoneal cancer (OVCA). Presented at the 12th Biennial Meeting of the International Gynecologic Cancer Society. Bangkok, Thailand; October 25, 2008.
28. Onda T, Kobayashi H, Nakanish T, et al.: Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG 0206. Gynecol Oncol 2009, 113:57-62.
29. Qayyum A, Coakley FV, Westphalen AC, et al.: Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecol Oncol 2005, 96:301-306.
30. Dowdy S, Mullany S, Brandt K, et al.: The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma. Cancer 2004, 101:346-352.
31. Axtell AE, Lee MH, Bristow RE, et al.: Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol 2007, 25:384-389.
32. Aletti GO, Dowdy SC, Gostout BS, et al.: Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 2006, 107:77-85.
33. Chi DS, Ven Ktraman ES, Masson V, et al.: The ability of preoperative serum CA125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 2000, 77:227-231.
34. Obeidat B, Latimer J, Crawford R: Can optimal cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA125 level. Gynecol Obstet Invest 2004, 57:153-156.
35. Gemer O, Lurain M, Goalevich M, et al.: A multicenter study of CA125 as a predictor of non-optimal primary cytoreduction of advanced epithelial ovarian cancer. Eur J Surg Oncol 2005, 31:1006-1010.
36. Chi DS, Franklin CC, Levine DA, et al.: Improved optimal cytoreduction rates for stage IIIC and IV epithelial ovarian, fallopian tube, primary peritoneal cancer: A change in surgical approach. Gynecol Oncol 2004, 94:650-654.
37. Deffieux C, Castaigne D, Pomel C: Role of laparoscopy to evaluated candidates for complete cytoreduction in advanced stages of epithelial ovarian cancer. Int J Gynecol Cancer 2006, 16:35-40.
38. Fagotti A, Ferrandina G, Fanfani F, et al.: A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: A pilot study. Ann Surg Oncol 2006, 13:1156-1161.
39. Geisler JP, Linnemeier GC, Thomas AJ, et al.: Nutritional assessment using prealbumin as an objective criterion to determine whom should not undergo primary radical cytoreductive surgery for ovarian cancer. Gynecol Oncol 2007, 106:128-131.
40. Schwartz PE, Zheng W: Neoadjuvant chemotherapy for advanced ovarian cancer: The role of cytology in pretreatment diagnosis. Gynecol Oncol 2003, 90:644-650.
41. Dodge JE, Mackay H, Klachook S, et al.: What is the optimal strategy to confirm the diagnosis of epithelial ovarian carcinoma (EOC) prior to neoadjuvant chemotherapy (NAC) ? J Clin Oncol 2009, 27:279S.
42. Columbo P-E, Mourregot A, Fabbaro, et al.: Aggressive surgical strategies in advanced ovarian cancer: A monocentric study of 203 stage IIIC and IV patients. EJSO 2009, 35:135-143.
43. Armstrong DK, Bundy B, Wenzel L, et al.: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006, 354:34-43.
44. Vergote I, De WI, Tjalma W, et al.: Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: A retrospective analysis of 285 patients. Gynecol Oncol 1998, 71:431-436.
45. Raffi A, Deval B, Geay J-F, et al.: Treatment of FIGO stage IV ovarian carcinoma: Results of primary surgery or interval surgery after neoadjuvant chemotherapy: A retrospective study. Int J Gynecol Cancer 2007, 17:777-783.
46. Zamagni C, DeIaco P, Rosati M, et al.: Effect of six courses of neoadjuvant chemotherapy on pathological complete remission in advanced ovarian cancer. J Clin Oncol 2009, 27:280S.
47. Gasowska-Bodner A, Bodnar L, Benedykt WG, et al.: CA125 regression after two cycles of neoadjuvant chemotherapy as prognostic factor in patients with advanced ovarian cancer and primary peritoneal serous cancer who underwent interval surgical cytoreduction. Ginekol Polska 2008, 79:108-114.
48. Bland AE, Everett EN, Pastore WA, et al.: Predictors of suboptimal surgical cytoreduction in women with advanced epithelial ovarian cancer treated with initial chemotherapy. Int J Gynecol Cancer 2008, 18:629-636.
49. de Jong D, Dodge JE, Freedman O, et al.: Predictors for optimal cytoreduction following neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma. J Clin Oncol 2009, 27:280S.
50. Tiersten AD, Liu PY, Smith HO, et al.: Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group study S0009. Gynecol Oncol 2009, 112:444-449.